Lineage Cell Therapeutics (LCTX) Liabilities and Shareholders Equity (2010 - 2026)

Lineage Cell Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $109.5 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 1.99% year-over-year to $109.5 million; the TTM figure through Mar 2026 stood at $402.6 million (down 5.14% YoY), while the FY2025 annual figure was $112.6 million, down 0.56% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $109.5 million, down from $112.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $144.5 million in Q1 2022, with the low at $89.6 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $111.7 million (2023), against an average of $111.9 million.
• Peak annual rise in Liabilities and Shareholders Equity reached 12.97% in 2022, while the deepest fall reached 29.15% in 2022.
• Lineage Cell Therapeutics' Liabilities and Shareholders Equity stood at $123.7 million in 2022, then retreated by 18.31% to $101.0 million in 2023, then climbed by 12.08% to $113.2 million in 2024, then fell by 0.56% to $112.6 million in 2025, then retreated by 2.71% to $109.5 million in 2026.
• Business Quant data shows LCTX's Liabilities and Shareholders Equity at $109.5 million in Q1 2026, $112.6 million in Q4 2025, and $89.6 million in Q3 2025.